A consortium composed of Italian and Spanish partners is willing to submit a Fast Track to Innovation (deadline 27/10/2020) proposal for the development of an electronic nose to rapidly and efficiently identify COVID positivity in patients. The device is ready for testing and validation, for which a medical Laboratory already performing COVID tests with current methods is sought. The partner for a Research and cooperation agreement should not be from Spain and Italy.

The project involves different partners, both private and public entities, from Italy and Spain, in order to realize an “electronic nose” able to sniff the positivity to the COVID virus in a person.

The nose has already been tested with good result being able to recognize the positivity between several unknown samples.

Current players are completing the development of the system. In order to ultimate the tool and ensure the reliability of the results, they are looking for a partner that should be a laboratory with the role of testing the device in the final phase of the project and while performing the test with current methods (either buffer or serological), compare the results to the ones obtained by the system and create a final database with every result stored properly in order to verify the compliance of the technology.

The project will be submitted to Fast Track to Innovation call (H2020-FTI-2018-2020) on October 27th deadline, EoIs expected by October 15th. Project duration 2 years. The partner must not be based in Italy or Spain.

The device will permit a fast and reliable testing of positive patients and once validated will become an efficient and fast alternative to current methodologies (buffer and serological tests) to identify the presence of the COVID infection, permitting to speed-up epidemy screening.

The partner should be a medical laboratory which performs COVID tests with current methods (either buffer or serological), and which will use the device to test it in the final phase of the project, comparing the results and creating a final database in order to verify the compliance of the technology.

The electronic device has already been tested with good results, being able to recognize the positivity between several unknown samples.

The device has been developed. IP rights will be assessed during the project

The partner will have a role as final user; it should be a medical laboratory which performs Covid tests with current methods (either buffer or serological), and which will be able to use the device to test it in the final phase of the project, comparing the results and creating a final database in order to verify the compliance of the technology. 

The partner should not be from Italy and Spain, in order to fit the FTI eligibility conditions (between three and five legal entities established in at least three different EU States)